Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
About us
Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel oncolytic immunotherapies. We imagine a world where cancer is a curable disease.
- Website
-
http://www.replimune.com
External link for Replimune
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Woburn, MA
- Type
- Public Company
- Founded
- 2015
Locations
-
Primary
Get directions
Woburn, MA 01801, US
Employees at Replimune
Updates
-
Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
-
Thank you for visiting our HQ in Woburn, BiotechTV! Check out Brad's full conversation with CEO Sushil Patel on the path forward for Replimune following our positive, topline primary analysis data by independent central review of RP1 plus nivolumab for anti-PD1 failed melanoma: https://lnkd.in/gu2MrmJq
-
Today, we announced a $100M financing, which follows the strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma. Proceeds will enable full commercial scale up to support a potential launch in 2H 2025. Read more: https://lnkd.in/eJFizq2q
-
-
We had an amazing time at #ASCO24! We were honored to present the latest data demonstrating our clinical progress in oncolytic #immunotherapy across our portfolio. Missed our presentations? Our posters and data can be found at ir.replimune.com.
-
-
Today, we shared topline primary analysis results by independent central review from our IGNYTE clinical trial of RP1 + nivolumab in anti-PD1 failed #melanoma. Read more: https://lnkd.in/gPmk-CbW
-
Today at #ASCO24 we will present RP1 / IGNYTE data in anti-PD-1-failed melanoma and RP2 data in uveal melanoma. Learn more about these two oral presentations here: https://lnkd.in/epTUWjzg
-
We are excited to be in Chicago for #ASCO24 to learn all about the latest and greatest advancements in #oncology – don’t miss us at Booth #16143 or at one of our presentations! https://lnkd.in/eYGVSpMP
-
-
Today, Replimune reported fiscal Q4 and year ended 2024 financial results and provided corporate updates: https://lnkd.in/ejqa2mad
-